Category Archives: Cardiovascular Pharmacology

South San Francisco Nov 6, 2019 (Thomson StreetEvents) -- Edited Transcript of Cytokinetics Inc earnings conference call or presentation Thursday, October 31, 2019 at 8:30:00pm GMT * Ching W. Jaw * Robert I. Blum H.C. Continue reading →

First heart transplant in Canada was performed at the Montreal Heart Institute First heart transplant in Canada was performed at the Montreal Heart Institute Fondation de lInstitut de Cardiologie de Montral MONTREAL, Quebec, Oct. 31, 2019 (GLOBE NEWSWIRE) -- The Montreal Heart Institute is proud to announce that the milestone of 500 heart transplants has been successfully completed recently. Continue reading →

Investigational therapy AD-214 raised no safety concerns in preliminary studies in non-human primates, and AdAlta, the therapys developer, is now planning to launch a Phase 1 clinical trial in humans, the company announced. AD-214 is amodification of AdAltas original lead candidate for the treatment of pulmonary fibrosis (PF), AD-114. AD-214 contains two i-bodies modified antibodies that specifically target the protein CXCR4 Continue reading →

Healthcare is an industry that is currently being transformed using the latest technology, so it can meet the challenges it is facing in the 21st century. Technology can help healthcare organizations meet growing demand and efficiently operate to deliver better patient care. Here are 9 technology trends that will transform medicine and healthcare in 2020 Continue reading →

The Advanced Drug Delivery Systems Market research report 2019-2024 focuses on the major drivers, restraints, opportunities and threats for key players. It also provides granular analysis of market share, segmentation, revenue forecasts and regional analysis till 2024. Continue reading →

High blood pressure is often branded the silent killer because it tends to creep up announced and only reveal itself when it is serious. The condition can raise a persons risk of developing deadly cardiovascular complications. Continue reading →

GPCRs market comprises assays and kits that aid in drug discovery and development. GPCRs is a large family of cell surface receptors that respond to a diverse range of external stimulus and play a major role in modern pharmacology due to their significant function in cell communication. More than 30% of the drugs available in the global market target GPCRs and most of the drugs that are currently under clinical and preclinical studies target this highly studied receptor protein Continue reading →

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verve Therapeutics, a next-generation cardiovascular company developing therapies that safely edit the adult human genome to permanently reduce a persons risk of coronary artery disease, today announced the appointment of physician and scientist Andrew Bellinger, M.D., Ph.D., as the companys chief scientific officer. Dr Continue reading →

Dr. Continue reading →

NDA Partners Chairman Carl Peck, MD, announced today that Klaus Peter Hoffmann, MD, PhD, a well-respected preclinical drug development expert with a focus in the cardiovascular and metabolic disease therapeutic areas, has joined the firm as an Expert Consultant. Dr. Continue reading →